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Abstract 
Executive dysfunctions are considered to be putative markers of familial/genetic vulnerability 
to both schizophrenia and bipolar disorder. However, familial resemblance must be 
demonstrated before executive functions are used as a potential endophenotype. The aim of 
this study was to investigate familial resemblance for executive functions in families of 
schizophrenic and bipolar subjects. We assessed executive functions by means of two tests – 
the Wisconsin Card Sorting Test (WCST) and the Trail Making Test (TMT) - in 351 subjects 
from five populations: schizophrenic patients, bipolar patients, a group of relatives for each 
patient group and controls. For both tests, cognitive assessment results were consistent with 
previous studies: schizophrenic patients showed the greatest impairment, followed by bipolar 
patients and then the two groups of relatives. In families of bipolar patients we observed 
familial resemblance for the WCST  and part A and part B of the TMT. However, by contrast 
with the classical point of view, considering executive measures to be markers of genetic 
vulnerability to schizophrenia, we did not demonstrate familial resemblance for either of the 
two executive tests in families of schizophrenic patients. Thus, executive measures, as 
assessed by WCST or TMT, should not be used as endophenotypes in genetic studies of 
schizophrenia unless confounders are identified and their effects eliminated. 
 
Key-words: executive dysfunction, genetics, endophenotype, cognition  
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Introduction 
Despite the existence of strong evidence for a genetic component in schizophrenia and bipolar 
disorder, no single gene has convincingly been shown to increase the risk for those disorders. 
One reason for this is the complexity of psychiatric disorders at the clinical and etiological 
level. Several authors (Gottesman and Shields, 1973; Leboyer et al., 1998; Freedman et al., 
1999; Leboyer, 2003) have advocated the use of the endophenotype approach to circumvent 
this problem. Endophenotypes are measurable traits, associated with the liability to the 
disorder and having a simple genetic determinism. As such, they provide a means of reducing 
clinical and genetic heterogeneity in psychiatric research. Gottesman and Gould (2003) 
recently summarized criteria for a good (i.e. an useful) endophenotype as follows : a) 
associated with illness, b)  more frequent in non-affected relatives than in general population, 
c) heritable and d) associated with a candidate gene or gene region. Several authors have 
suggested that measures of executive functions (EF) could be used as endophenotypes in 
schizophrenia and bipolar research. EF are cognitive processes that allow the subject to adapt 
to unusual situations in which automated responses are not sufficient. Among various tests 
that are used to assess EF, the Wisconsin Card Sorting Test (WCST) and the Trail Making 
Test (TMT) are of particular interest as they are well standardized and widely used and could 
represent, at least in  families of schizophrenic probands, markers of two distinct risk factors 
(Yurgelun-Todd and Kinney 1993). Using these two tests, executive dysfunctions were 
repeatedly found in schizophrenic patients (Koren et al. 1998, Bustini et al. 1999, Laurent et 
al. 2000), and impairment has also been detected in most studies concerning bipolar patients 
(Coffman et al. 1990, Morice 1990, Ferrier et al. 1999), although some exceptions are known 
(Rubinsztein et al. 2000). Several studies of relatives of schizophrenic or bipolar patients have 
investigated whether executive dysfunctions could be used as a marker of familial 
vulnerability. Recently, two meta-analyses (Sitskoorn et al. 2004, Szöke et al. 2005) showed 
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that relatives of schizophrenic patients have impaired performances on tests of executive 
functions. The impairments observed were less severe than those observed in patients. Fewer 
studies have compared the relatives of bipolar patients with controls (Kremen et al. 1998, 
Keri et al. 2001) and no firm conclusions can be drawn from the results obtained in these 
studies. In a previous study, we (Zalla et al. 2004) found no significant difference in WCST 
or TMT scores between relatives of bipolar patients and controls. However, this may reflect 
the limited statistical power of the study, due to small sample sizes. 
The heritability of executive impairments was assessed by calculating relative risk in siblings 
of schizophrenic patients (Egan et al. 2001a). In this population, the authors found an 
increased risk of impaired performance in Trails B and WCST (4.0 and 2.0 respectively). 
However, relative risk is not a direct measure of heritability. Instead, as pointed out by Egan 
et al. (2001a) it assesses its upper limit.  
Based on these results and on the hypothesis linking EF and catechol-O-methyl transferase 
(COMT) activity (see Weinberger et al. 2001 for further discussion), several studies have 
looked for an association between executive dysfunctions and COMT gene polymorphisms in 
schizophrenic patients and their relatives. The Val158Met functional polymorphism of the 
COMT gene was found to affect WCST performance if schizophrenic patients and controls 
were pooled together (Egan et al. 2001b, Joober et al. 2002), but not if schizophrenic patients 
were assessed separately (Rosa et al. 2002, Bilder et al. 2002, Ho et al. 2005). This effect was 
also found in the siblings of schizophrenic patients in one study (Rosa et al. 2002) but not in 
another (Egan et al. 2001b). It was also found in healthy volunteers (Malhotra et al. 2002). In 
bipolar subjects, a positive association was found between WCST performance and a 
polymorphism (Val66Met) of another candidate gene, the brain-derived neurotrophic factor 
(BDNF) gene (Rybakowski et al. 2003). Inconsistencies in the results of association studies 
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using WCST score as the endophenotype may be accounted for by as yet unidentified 
confounders, which could limit the value of EF as an endophenotype.  
 
The aim of our study was to investigate the causes of discrepancies between the promising 
results of studies showing impairments in patients and their relatives and the disappointing 
results of association studies. To do this we assessed familial resemblance for performances 
on two widely used tests of EF – the WCST and the TMT - in families of schizophrenic and 
bipolar patients. Familial resemblance, which, unlike relative risk, is sensitive to incorrect 
individual evaluation and classification (i.e. to confounders not accounted for), is an indicator 
of actual heritability and, as such, is a more stringent indicator of the usefulness of a putative 
endophenotype for genetic research. 
Discrepancies between studies investigating executive dysfunctions may be partly explained 
by differences in inclusion criteria for bipolar patients (euthymic or not), for relatives 
(including or excluding affected relatives) and for controls (including or excluding controls 
with a positive family history). To limit the probability of identifying spurious differences due 
to the inclusion of acutely ill patients and of false negative results due to “fuzzy” borders 
between groups, we used strict inclusion criteria. We included only patients in remission and 
excluded subjects presenting a personal history of psychotic or bipolar disorders from the 
non-patient groups, and subjects with affected first-degree relatives from the control group.  
Methods 
Subjects  
Patients meeting DSM-IV (American Psychiatric Asociation, 1994) criteria for bipolar 
disorder or schizophrenia were consecutively recruited at two university-affiliated hospitals 
(the Pitié-Salpétrière and Albert Chenevier hospitals, Paris). They were included in the study 
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just before discharge. To confirm the diagnosis of bipolar disorder or schizophrenia in 
probands, patients were interviewed by an experienced psychiatrist with the French version  
of the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger et al., 1996; Preisig et 
al., 1999). First-degree relatives of patients were also contacted and asked to participate in 
the study. Relatives were interviewed with the DIGS to exclude those presenting psychotic or 
bipolar disorder. Relatives which met criteria for schizophrenia or bipolar disorder were  
included in the patients groups. Familial psychiatric morbidity was also investigated using the 
Family Interview for Genetic Studies (FIGS) (Maxwell, 1992). A complete family history of 
first-degree relatives was obtained from each proband and from at least one first-degree 
relative. The information was supplemented, if required, with data from the medical case 
notes. 
Healthy controls were blood donors at the Pitié-Salpétrière Hospital. Controls were included 
after being interviewed with the DIGS and the FIGS to confirm the absence of a personal and 
family history of DSM IV axis I or II disorders. 
For inclusion in the study, all subjects (patients, relatives and controls) had to be 
normothymic, as evaluated by the Montgomery and Asberg depression rating scale (MADRS) 
(Montgomery and Asberg, 1979) and the Bech and Rafaelsen mania rating scale (MAS) 
(Bech et al., 1978). Schizophrenic and bipolar patients were also required to be in a stable 
state, with no change in medication or symptoms for at least two weeks before cognitive 
evaluation. All patients and some of the relatives were medicated at the time of cognitive 
assessment. No inclusion or exclusion criteria based on medication were used and as a 
consequence individual prescriptions varied widely in dosage, number of different molecules 
and type of medication (antipsychotics – classical or atypical, mood stabilizers, 
antidepressants, anxiolytics, anticholinergic agents etc.) For this reason description of 
medication for each subject could not be done in a homogeneous way and was not recorded. 
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This is the usual situation in studies using cognitive measures as putative endophenotypes in 
unselected samples of schizophrenic subjects (for example Egan et al 2001, Ho et al 2005). 
Patients and relatives were included only if they were aged between 18 and 60 years, and had 
no history of neurological disease or current substance abuse.  
The research ethics board of Salpêtrière Hospital reviewed and approved the study. The study 
was described in detail to the subjects, who then gave written informed consent for 
participation. 
In this study, we included also 137 subjects (25 schizophrenic patients, 22 relatives of 
schizophrenic patients, 37 bipolar patients, 33 relatives of bipolar patients and 20 controls), 
for whom cognitive evaluation, with a larger battery of cognitive tests, has already been 
reported (Zalla et al. 2004). 
 
Cognitive assessment 
We used the classic form of the WCST (Heaton 1981) with four stimulus cards differing in 
three characteristics: color (yellow, green, red, blue), shape (triangle, star, cross, circle) and 
number (one to four) and two identical sets of 64 response cards. The test was discontinued 
after the completion of six categories or when no more response cards remained. 
The two measures most often used to assess WCST performance are the number of categories 
completed and number of perseverative errors. However, as the number of categories shows 
an important ceiling effect, the only measure we used in our analysis was number of 
perseverative errors. 
The Trail Making Test (Reitan and Wolfson, 1985) is a pencil and paper test assessing 
psychomotor speed, attention and set alternation. Part A requires the subjects to connect 25 
consecutively numbered circles as quickly as possible. In Part B, the subjects have to connect 
25 consecutively numbered and lettered circles by alternating between the two sets.  
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In this study we used three measures derived from the TMT : time to complete Part A, time to 
complete Part B and the difference between the two parts of the test (time B-A) The time 
taken to complete Part A depends mainly on visual scanning and motor speed. Because Part B 
of the TMT is influenced by cognitive flexibility the time taken to complete Part B is 
considered a measure of EF. The difference between the two parts of the test is used to 
eliminate performance variation due to psychomotor speed (Lezak 1995), and the resulting 
value is considered a more specific measure of EF. 
Statistical methods 
Group comparison, for executive performances, was done by analysis of covariance 
(ANCOVA), with sex, age, and study level used as the covariates. Bilateral comparisons of 
interest (between schizophrenic and bipolar patients, between the groups of patients and their 
respective relatives, between the two groups of relatives and between controls and each of the 
other groups) were carried out using contrasts. We used Bonferroni correction for eight 
comparisons to reduce type I errors due to multiple tests, setting the threshold for significant 
results at 0.00625. 
 
Familial resemblance was assessed in families for which two or more members, affected or 
not, had completed the cognitive tests. To ensure that this assessment was independent of 
factors likely to influence cognitive performance, we calculated residuals by subtracting the 
predicted performance from the actual performance. Performance was predicted by means of 
a generalized linear model in which we included all significant explanatory variables. 
 
Finally, we carried out an ANOVA, with family membership as an independent variable, to 
assess the effect of family membership on the residuals calculated in the previous step. This 
procedure was used for the total sample and separately for schizophrenic and bipolar families. 
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All analyses were carried out with the SAS 
®
 V8 package. 
 
Results 
The final sample consisted of 351 subjects: 74 schizophrenic patients, 68 of their  relatives, 97 
bipolar patients,  64 of their relatives  and 48 controls. Their demographic characteristics are 
summarized in Table 1. Highest completed school grade was recorded, according to the usual 
conventions (Pichot et al. 1993) as a trichotomous variable (1 = elementary school; 3 = at 
least high school completed; 2 = intermediate between 1 and 3). However, as no level 1 
subjects were present in three groups and as such subjects were also rare in the other groups, 
we decided to pool the first two levels together in subsequent analysis.  
Insert Table 1 
 
The results of cognitive assessment are summarized in table 2. 
 
Insert Table 2. 
Familial resemblance was assessed in 75 families (37 schizophrenic and 38 bipolar 
pedigrees), for a total of 196 subjects. 
 
TMT 
As sex had no significant effect on any of the TMT scores, all comparisons were adjusted 
only for age and school grade.  
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Part A. Significant differences were found between groups (p<0.0001). Schizophrenic 
patients differed significantly from their relatives (p<0.0001), from bipolar patients 
(p=0.0004) and from controls (p<0.0001) and bipolar patients differed significantly from 
controls (p<0.0001). No significant difference emerged in comparisons of the groups of 
relatives with controls or of bipolar patients and their relatives. 
Familial resemblance was significant in the total sample (F=1.51, df= 72, p=0.025) and in BP 
pedigrees (F=2.37, df= 36, p=0.0017), but not in schizophrenic pedigrees (F=0.83, df= 36, 
p=0.72). 
Part B. The five groups significantly differed in their results (p<0.0001). Contrasts showed 
that schizophrenic subjects had significant impairments when compared to their relatives 
(p<0.0001), controls (p<0.0001) and bipolar subjects (p<0.0001). Significant differences were 
also observed when controls were compared to bipolar patients (p<0.0001), with relatives of 
schizophrenic subjects (p=0.0018) and with relatives of bipolar subjects (p=0.0045) 
For part B of the TMT there was no significant familial resemblance in the total sample 
(F=1.32, df= 72, p=0.093) or in schizophrenic pedigrees (F=1.11, df= 36, p=0.36). However 
in BP pedigrees significant familial resemblance was observed (F=1.86, df= 36, p=0.017). 
B-A difference. Significant differences were found between groups (p<0.0001). Schizophrenic 
patients differed significantly from their relatives (p=0.0006), from bipolar patients 
(p=0.0053) and from controls (p<0.0001) and bipolar patients differed significantly from 
controls (p=0.0005). No significant difference emerged in comparisons of the groups of 
relatives with controls or of bipolar patients and their relatives. 
We found no statistically significant familial resemblance in executive performance, assessed 
as the difference between Trail B and Trail A results, in the total sample (F=1.17, df= 72, 
p=0.22) or in the schizophrenic (F=1.13, df= 36, p=0.43) and bipolar (F=1.33, df= 36, 
p=0.20) pedigrees assessed independently. 
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WCST 
Sex had no significant effect on perseverative errors scores in the WCST. ANCOVA adjusted 
for age and school grade showed significant differences between the five groups (p<0.0001).  
Bilateral comparisons revealed that schizophrenic patients  differed from their relatives 
(p=0.0028), from bipolar patients (p=0.0013) and from controls (p<0.0001). No significant 
difference was identified between bipolar patients and control, between groups of relatives 
and controls or between bipolar patients and their relatives. 
For the number of perseverative errors, we found a familial resemblance in the total sample 
(F=1.79, df= 71, p=0.003) and in BP pedigrees (F=2.94, df= 36, p=0.0001), but not in 
schizophrenic pedigrees (F=1.14, df= 35, p=0.76). 
 
One possible reason for the negative results obtained when assessing familial resemblance for 
EF in  schizophrenic families, in contrast with significant familial resemblance in bipolar 
families for TMT B and WCST is that the models used to predict performances on those tests 
are not as good for schizophrenic as for bipolar pedigrees. We therefore calculated the SD of 
residuals as a rough estimate of the fit of the models. For the WCST the values obtained for 
this estimator were higher for schizophrenic patients (21.0) than for the three other groups 
(16.1 for schizophrenic relatives, 15.7 for bipolar relatives and 12.6 for bipolar patients). 
Similar results were obtained for the TMT B (59.7 in schizophrenic patients, 30.1 in their 
relatives, 43.8 for bipolars and 31.8 in the group of relatives of bipolar patients) thus 
suggesting that the models used may predict performance less accurately for schizophrenic 
patients.  
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Discussion 
By contrast with the classical point of view considering executive dysfunctions to be markers 
of genetic vulnerability to schizophrenia, we did not demonstrate familial resemblance for 
two widely used tests (WCST and Trail) in the families of schizophrenics patients. However, 
we observed familial resemblance for WCST and for Trails A and B performances in BP 
families.  
The lack of familial resemblance within the families of schizophrenic patients was unexpected 
as there is strong evidence for executive dysfunction in schizophrenic patients (Heinriks and 
Zakzanis  1998, Johnson-Selfrige and  Zalewski 2001) and their relatives (Snitz et al. 2003, 
Szöke et al. 2005). There are two possible explanations for our findings: either performances 
in these two tests are not influenced by familial factors, or the limitations of our study 
prevented us from demonstrating familial resemblance. Several lines of evidence from this 
and previous studies suggest that the two EF tests used are influenced by familial factors. 
First, impairments have been demonstrated in the relatives of schizophrenic patients for both 
TMT and WCST in most studies and have been validated by a meta-analysis of published 
data (Szöke et al. – 2005). Second, several studies using the WCST as an endophenotype have 
demonstrated associations between candidate genes (COMT or BDNF) in general population 
(Malhotra et al. 2002), in bipolar patients (Rybakowski et al. 2003), and in the relatives of 
schizophrenic patients (Rosa et al. 2002), but not in schizophrenic probands (Rosa et al. 2002, 
Bilder et al. 2002, Ho et al. 2005). Finally, we observed, in this study, familial resemblance in 
the families of bipolar patients. Thus, performances in EF tests, as shown by these data 
obtained in different populations, are clearly influenced by familial factors. However, we 
detected no familial resemblance in the families of schizophrenic patients. This apparent 
discrepancy may be accounted for by several potential limitations of this study.  
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First, our sample of relatives may be unrepresentative as not all the relatives approached 
agreed to participate in the study. Familial resemblance for EF may therefore be obscured 
because the relatives included may be preferentially those who do not carry the cognitive 
endophenotype and may have EF measures similar to controls. This seems unlikely as our 
results for controls and relatives are similar to those already published in the literature. A lack 
of statistical power may also account for the lack of detection of familial resemblance in 
schizophrenic families, but this also seems unlikely as we obtained significant results for 
bipolar families with a similar sample size. Finally, confounders not accounted for in our 
study may explain this negative result. The absence of familial resemblance for WCST in 
schizophrenic families may result from some sources of heterogeneity in executive 
performances not being taken into account, in particular in probands. Indeed, the SD of 
residuals were larger in schizophrenic probands than in the other groups of subjects. Further 
support for this hypothesis is provided by the observation that, if WCST score is used as an 
endophenotype in association studies, positive results are obtained in BP patients 
(Rybakowski et al. 2003), in general population (Malhotra et al. 2002), in the relatives of 
schizophrenic patients (Rosa et al. 2002) and in mixed samples (Egan et al. 2001b, Joober et 
al. 2002) but not in schizophrenic probands alone (Egan et al. 2001b, Bilder et al. 2002, Rosa 
et al. 2002, Joober et al. 2002, Ho et al. 2005).  Altogether, we suggest that confounding 
factors usually not taken into account influence executive measures in patients with 
schizophrenia and could be the cause of negative association studies. These potential 
confounders in schizophrenic patients may include treatment, illness duration, motivation and 
symptoms. In a meta-analysis of EF studies in schizophrenic patients, Johnson-Selfrige and 
Zalewski (2001) found that positive and negative symptoms and number of hospital 
admissions influenced EF. In future studies testing cognitive endophenotypes as markers of 
vulnerability to schizophrenia, such variables should therefore be taken into account.  
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Another potential problem concerns the statistical methods. Different methods could be used 
to calculate the residuals. First, normative data from large normal samples are available (for 
example Taubaugh 2004, Drane et al 2002) and could be used to calculate residuals. 
However, there is no enough evidence to support the use of these data in pathological samples 
and/or in their relatives. 
Another method consists in calculating separate residual curves for each sample 
(schizophrenic subjects, bipolars and their relatives). To be reliable such method necessitate 
large individual samples, not usually available.  
In our study we used all available subjects to calculate the influence of demographic and 
diagnostic variables. This is the method usually used in studies on cognition in schizophrenic 
and bipolar subjects and their relatives (see for example Laurent et al 1999, Krabbendam et al. 
2001). We chose this method because our aim was to assess if cognitive measures, as 
currently used, are good potential endophenotypes. Further studies are needed to evaluate the 
impact of the different methods used to calculate the influence of demographic variables in 
non-normal samples. 
We detected familial resemblance for WCST in BP families. Nevertheless, two caveats should 
be placed on the use of this measure as an endophenotype in genetic studies of bipolar 
disorder. The first is that the origin of familial resemblance may be genetic and/or 
environmental. Larger samples, and possibly particular types of samples (e.g. adoptees) are 
required to separate these two types of effect. A more important limitation is that, to date, few 
data are available supporting the association of executive dysfunctions with bipolar disorder 
and, especially, the presence of impairments in relatives. In our study, differences between 
controls and bipolar patients and between controls and relatives of bipolar patients were not 
statistically significant for the WCST. Although previous studies (reviewed in Quraishi and 
Frangou 2002) have suggested that bipolar patients display mild impairments in both WCST 
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and TMT, three studies using these tests found no difference between the relatives of bipolar 
patients and controls (Kremen et al.1998, Keri et al. 2001, Zalla et al. 2004). This suggests 
that impairment may be more state- than trait-related.  
The absence of familial resemblance for the TMT the B-A difference in bipolar families 
suggests that either this measure of EF is not subject to familial influence, or the familial 
effect is obscured by confounders that do not influence WCST results.  This suggests that 
these two measures of EF have different determinants. 
The separate analyses of  Trails A and B provided significant familial resemblance in bipolar 
families. These results and the negative result for the B-A difference suggest that visual 
scanning and motor processes, but not cognitive flexibility, are influenced by familial factors. 
As for WCST results, more research is needed before scores of Trail A and B could be 
considered potential endophenotypes for bipolar disorder. 
In conclusion, in this study we did not found familial resemblance in families of 
schizophrenic subjects for two measures of EF considered as potential endophenotypes. This 
negative result was observed using the usual methods for the inclusion of subjects and for the 
statistical analysis of data. This implies that efforts have to be made to address the present 
methodological limitations before these EF measures could be successfully used as 
endophenotypes in schizophrenia research.  
In contrast in bipolar families several cognitive measures (TMT part A and B, perseverative 
errors on the WCST) showed familial resemblance. Before they could be considered potential 
for bipolar disorder more research is needed to establish the association between executive 
dysfunction and vulnerability to bipolar disorder. 
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Table 1. Demographic characteristics of the five groups of subjects (schizophrenic patients, relatives of schizophrenic patients, bipolar patients, 
relatives of bipolar patients and controls) 
 
 Schizophrenic 
patients 
Relatives of 
schizophrenic 
patients 
Bipolar 
patients 
Relatives of 
bipolar 
patients 
Controls F (df) p 
N 73 67 95 63 48   
Age  
(mean +/- SD) 
33.0 +/- 9.0 
a
 44.7 +/- 12.9
 b
 40.5 +/- 11.0 40.7 +/- 13.0 42.2 +/- 13.2 9.31 (4) <0.0001 
Sex 
(% men)  
67.6 
a
 47.1 38.1 39.1 50.0 15.93 (4) 0.0031 
Education  
(% high school) 
41.9 
a
 79.4 86.6 82.8 62.5 
a
 48.59 (4) <0.0001 
 
a. significantly different, at 0.05 threshold, from the other groups; 
b. significantly different, at 0.05 threshold, from the bipolar subjects 
 23 
Table 2. Results of cognitive assessment, WCST and TMT, in the five groups of subjects (schizophrenic patients, relatives of schizophrenic 
patients, bipolar patients, relatives of bipolar patients and controls) 
 
  Schizophrenic 
patients 
Relatives of 
schizophrenic 
patients 
Bipolar 
patients 
Relatives of 
bipolar 
patients 
Controls F (df) p 
TMT N 73 67 95 63 48   
Part A  
(mean +/- SD) 
a
 
50.8 +/- 17.8 
 b,c,d
 39.4 +/- 14.3 41.4 +/- 16.0
 b
 37.1 +/- 15.9 32.6 +/- 11.5 15.84 (7) <0.00001 
Part B  
(mean +/- SD) 
a
 
123.4 +/- 67.0
 b,c,d
 85.1 +/- 35.0
 b
 88.7 +/- 47.8
 b
 78.3 +/- 33.7
 b
 63.4 +/- 24.1 23.27 (7) <0.00001 
B-A 
(mean +/- SD) 
a
 
72.6 +/- 58.1 
 b,c,d
 45.8 +/- 29.8 47.3 +/- 44.6 
b
 41.2 +/- 34.3 30.9 +/- 18.3 14.36 (7) <0.00001 
WCST N 66 63 96 63 48   
 
Perseverative 
errors 
(mean +/- SD) 
a
 
24.6 +/- 21.6 
b,c
 15.1 +/- 17.5 13.6 +/- 12.8 12.8 +/- 17.1 9.7 +/- 7.6 9.37 (7) <0.00001 
c. p for group effect < 0.0001, 
d. significantly different, at 0.00625 threshold, from controls, 
e. significantly different, at 0.00625 threshold, from their relatives 
f. significantly different, at 0.00625 threshold, from bipolar patients 
